Probiodrug Announces Top-Line Results of the First Clinical Study of PQ912 for Treatment of Alzheimer’s Disease

Probiodrug and Its Collaborators Will Present Novel Insights into the Pathophysiology of Alzheimer’s Disease at Society for Neuroscience’s Neuroscience 2011 Conference in Washington, D.C.
Probiodrug AG raises additional €15 Million to advance its clinical program